Lilly's Mounjaro Tops Other GLP-1s for Type 2 Diabetes Patients in New Trial
LLY sits 81% above its 52-week low of $623.78.
Summary
Eli Lilly's Mounjaro demonstrated superior efficacy over other GLP-1 drugs, including Novo Nordisk's semaglutide, in the SURPASS-EARLY trial. The study showed Mounjaro led to significantly better blood sugar control, weight reduction, and waist circumference improvements for type 2 diabetes patients not responding to initial treatment. Roughly 60% of Mounjaro patients achieved normal blood sugar levels after two years, compared to 24% in the control group. This new clinical data reinforces Mounjaro's competitive advantage and strengthens Eli Lilly's leadership in the rapidly growing GLP-1 market, following the company's exceptional Q1 2026 results driven by strong Mounjaro sales.
At the time of this announcement, LLY was trading at $1,129.03 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,149.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.